Fig. 6

MSC expansion in optimized CDM validates maintenance of immunomodulatory bioactivity and enhanced proliferation compared to SCM. (A) MSC proliferation fold change for each media type after one passage. (B) IDO activity measured by L-kynurenine levels normalized to cell number for each media type; analyzed using one-way ANOVA with Dunnett’s post-hoc test to determine significance between hits and + CTL (n = 5 technical replicates). (C) sICAM-1 secretion normalized to cell number for each media type; analyzed using one-way ANOVA with Dunnett’s post-hoc test to determine significance between hits and + CTL (n = 5 technical replicates). The dashed line represents respective values for SCM after P1 of the initial expansion (i.e. data presented in Fig. 4). *p < 0.05 compared to Hit G (+ CTL)